培瑞高以45亿美元收购欧米茄制药，成为欧洲五大非处方药生产商

Pharmadeals Review Pub Date : 2014-11-22 DOI:10.3833/PDR.V2014I11.2077

Sayani Datta, Heather Cartwright

{"title":"培瑞高以45亿美元收购欧米茄制药，成为欧洲五大非处方药生产商","authors":"Sayani Datta, Heather Cartwright","doi":"10.3833/PDR.V2014I11.2077","DOIUrl":null,"url":null,"abstract":"Continuing the unprecedented wave of consolidation seen in the OTC pharmaceutical sector thus far in 2014, Perrigo has agreed to acquire Belgium-based Omega Pharma for €3.6 B (US$4.5 B), including the assumption of €1.1 B (US$1.4 B) in debt. The deal will accelerate Perrigo’s international growth strategy, diversifying its revenue streams and giving it access to an established commercial infrastructure in Europe.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"112 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Perrigo to Become Top 5 OTC Player in Europe with US$4.5 B Omega Pharma Acquisition\",\"authors\":\"Sayani Datta, Heather Cartwright\",\"doi\":\"10.3833/PDR.V2014I11.2077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Continuing the unprecedented wave of consolidation seen in the OTC pharmaceutical sector thus far in 2014, Perrigo has agreed to acquire Belgium-based Omega Pharma for €3.6 B (US$4.5 B), including the assumption of €1.1 B (US$1.4 B) in debt. The deal will accelerate Perrigo’s international growth strategy, diversifying its revenue streams and giving it access to an established commercial infrastructure in Europe.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"112 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2014I11.2077\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2014I11.2077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

继2014年OTC医药行业前所未有的整合浪潮之后，Perrigo同意以36亿欧元(45亿美元)收购比利时的Omega Pharma，其中包括承担11亿欧元(14亿美元)的债务。这笔交易将加速佩里戈的国际增长战略，使其收入来源多样化，并使其能够进入欧洲成熟的商业基础设施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Perrigo to Become Top 5 OTC Player in Europe with US$4.5 B Omega Pharma Acquisition

Continuing the unprecedented wave of consolidation seen in the OTC pharmaceutical sector thus far in 2014, Perrigo has agreed to acquire Belgium-based Omega Pharma for €3.6 B (US$4.5 B), including the assumption of €1.1 B (US$1.4 B) in debt. The deal will accelerate Perrigo’s international growth strategy, diversifying its revenue streams and giving it access to an established commercial infrastructure in Europe.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量